8-KItem 2.02 · Results of OperationsItem 5.02 · Officer/Director ChangeItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements
Centene raises 2026 EPS guidance and appoints Paul Diaz to its board
Filed with the SEC on · Summarized by InvestorsBot
Centene reported second-quarter 2026 revenue of $53.6 billion, GAAP diluted EPS of $2.19 and adjusted diluted EPS of $2.51, and raised its 2026 guidance to more than $3.11 in GAAP EPS and $4.80 in adjusted EPS. Effective July 28, Kenneth Burdick resigned from the board without citing any dispute, and Paul Diaz, a former Myriad Genetics and Kindred Healthcare CEO, joined the board and its Audit and Quality and Compliance committees.